Selective Agonists of Thyroid Hormone Receptor Beta for the Treatment of NASH

Nonalcoholic fatty liver disease (NAFLD) is a common condition associated with cirrhosis and hepatocellular carcinoma, affecting approximately 70% of people with obesity or type 2 diabetes.1 In the absence of approved pharmacotherapies, current guidelines1-3 recommend reversing nonalcoholic steatohepatitis (NASH) by targeting obesity or type 2 diabetes, either with weight loss from lifestyle intervention and the use of glucagon-like peptide-1 (GLP-1) receptor agonists or with the treatment of type 2 diabetes with an insulin sensitizer such as pioglitazone.1-3 Thyroid hormone modulates hepatic glucose and lipid metabolism.1 Hypothyroidism is associated with steatosis, although its role in steatohepatitis is difficult to separate from . . .